AUTOMATIC DRIVING SYSTEM FOR VEHICLE
    1.
    发明申请
    AUTOMATIC DRIVING SYSTEM FOR VEHICLE 审中-公开
    汽车自动驾驶系统

    公开(公告)号:US20160288791A1

    公开(公告)日:2016-10-06

    申请号:US14777534

    申请日:2014-03-18

    发明人: Su-Min PARK

    摘要: The present invention relates to an automatic driving system for a vehicle, and more specifically, to an automatic driving system for a vehicle which controls a vehicle to be automatically driven to a destination in consideration of traffic signals and peripheral vehicles or objects, when a driver sets the destination in a navigation device. To this end, the system according to the present invention comprises: a mapping module for setting a driving lane by receiving route information set in a navigation device installed in a vehicle and then, converting a distance, direction, and rotation angle to actual measurement data; and a driving control module for having a vehicle be driven along the driving lane set by the mapping module.

    摘要翻译: 本发明涉及一种用于车辆的自动驾驶系统,更具体地说,涉及一种车辆的自动驾驶系统,其中,当驾驶者驾驶员自动驾驶系统时,考虑交通信号和周边车辆或物体,将车辆自动地驱动到目的地 将目的地设置在导航设备中。 为此,根据本发明的系统包括:映射模块,用于通过接收设置在安装在车辆中的导航装置中的路线信息来设置行驶车道,然后将距离,方向和旋转角度转换为实际测量数据 ; 以及驱动控制模块,用于沿着由映射模块设置的行驶车道驱动车辆。

    Anticancer composition
    4.
    发明授权
    Anticancer composition 有权
    抗癌成分

    公开(公告)号:US08809297B2

    公开(公告)日:2014-08-19

    申请号:US13700668

    申请日:2010-05-28

    摘要: Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).

    摘要翻译: 公开了一种抗癌组合物,其包含针对WIG1和/或YPEL5的抑制剂或针对由该基因编码的蛋白质。 还提供了用于筛选抗癌剂的组合物,其包含具有与WIG1和/或YPEL5的mRNA互补的序列的核酸或由该基因编码的蛋白质的抗体。 另外,提供了筛选抗癌剂的方法,该方法包括:(A)定量分析未用抗癌剂候选物治疗的肿瘤细胞中mRNA或蛋白质水平的WIG1和/或YPEL5的表达; (B)定量分析治疗抗癌剂候选者后肿瘤细胞中mRNA或蛋白质水平的基因的表达; 和(C)与步骤(A)相比,如果在步骤(B)中基因的表达水平升高,则选择候选物。

    METHOD AND SYSTEM FOR TRACEPOINT-BASED FAULT DIAGNOSIS AND RECOVERY
    7.
    发明申请
    METHOD AND SYSTEM FOR TRACEPOINT-BASED FAULT DIAGNOSIS AND RECOVERY 有权
    基于TRACEPOINT的故障诊断和恢复方法与系统

    公开(公告)号:US20110138224A1

    公开(公告)日:2011-06-09

    申请号:US12787086

    申请日:2010-05-25

    IPC分类号: G06F11/14

    CPC分类号: G06F11/079

    摘要: A system for tracepoint-based fault diagnosis and recovery includes: a system state tracing model unit for storing state tracing models which are obtained by a modeling technique and are required for fault diagnosis and recovery; a state diagnosis unit for determining whether or not an action event is executable with reference to the state tracing models when the action event is received from a specific tracepoint among multiple tracepoints which exist in each of components within an operating system of the system, and generating a fault recovery command when it is determined that the action is not executable, that is, a fault has occurred; and a fault recovery unit for performing a fault recovery processing based on the state tracing models in response to the generated fault recovery command.

    摘要翻译: 用于基于跟踪点的故障诊断和恢复系统包括:用于存储通过建模技术获得并且是故障诊断和恢复所需的状态跟踪模型的系统状态跟踪模型单元; 状态诊断单元,用于当从所述系统的操作系统中的每个组件中存在的多个跟踪点中的特定跟踪点接收到所述动作事件时,参考所述状态跟踪模型来确定动作事件是否可执行,并且生成 确定动作不可执行的故障恢复命令,即已发生故障; 以及故障恢复单元,用于响应于所生成的故障恢复命令,基于状态跟踪模型执行故障恢复处理。